熊春锦,华宝来,夏炳兰.超声引导下关节腔内注射重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)治疗血友病性关节病[J].中国介入影像与治疗学,2022,19(4):202-205
超声引导下关节腔内注射重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)治疗血友病性关节病
Ultrasound-guided intra-articular injection of recombinant human tumor necrosis factor receptor-Fc fusion protein (etanercept) for treating hemophilic arthropathy
投稿时间:2021-09-08  修订日期:2022-01-16
DOI:10.13929/j.issn.1672-8475.2022.04.003
中文关键词:  血液凝集障碍,遗传性  关节疾病  肿瘤坏死因子  超声检查,介入性
英文关键词:blood coagulation disorders, inherited  joint diseases  tumor necrosis factor  ultrasonography, interventional
基金项目:扬州科技计划项目(YZ2021069)、苏北人民医院院级科研基金重点项目(yzucms202003)。
作者单位E-mail
熊春锦 苏北人民医院超声科, 江苏 扬州 225001  
华宝来 苏北人民医院血液科, 江苏 扬州 225001  
夏炳兰 苏北人民医院超声科, 江苏 扬州 225001 yzsbxbl@163.com 
摘要点击次数: 791
全文下载次数: 257
中文摘要:
      目的 观察超声引导下关节腔内注射重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)治疗血友病性关节病(HA)的价值。方法 回顾性分析32例接受超声引导下穿刺关节腔注射益赛普的HA患者,对比观察治疗前及治疗后1个月血友病关节健康评分(HJHS)、视觉模拟评分(VAS),以及超声所示目标关节增生滑膜厚度、血流信号、Melchiorre及中国早期血友病性关节病超声检测(HEAD-US-C)评分,评估其治疗价值。结果 对32例均成功完成超声引导下穿刺关节腔及腔内注射益赛普,共对18例膝关节、7例肘关节及7例踝关节进行治疗。术后未出现感染、出血等并发症。治疗后1个月,目标关节HJHS、VAS、Melchiorre评分、HEAD-US-C评分及增生滑膜最大厚度、平均厚度、血流信号均低于治疗前(P均<0.01)。结论 超声引导下关节腔内注射益赛普治疗HA安全、有效。
英文摘要:
      Objective To observe the value of ultrasound-guided intra-articular injection of recombinant human tumor necrosis factor receptor-Fc fusion protein (etanercept) for treating hemophilic arthropathy (HA). Methods Data of 32 HA patients who underwent ultrasound-guided intra-articular injection of etanercept were retrospectively analyzed. The hemophilia joint health scores (HJHS), visual analogue scale (VAS), the thickness and blood flow signals of proliferative synovial membrane, Melchiorre scale, hemophilic early arthropathy detection with ultrasound in China (HEAD-US-C) score of target joints before and 1 month after treatment were observed and compared. The value of ultrasound-guided intra-articular injection of etanercept for treating HA was analyzed. Results Ultrasound-guided percutaneous intra-articular injection of etanercept was successfully completed in all 32 cases, including keen joint of 18 cases, elbow joint of 7 cases and ankle join of 7 cases. No complication such as infection and bleeding occurred. One month after treatment, the HJHS, VAS, Melchiorre scale, HEAD-US-C scores, and the maximum thickness,the average thickness and blood flow signals of proliferative synovial membrane of target joint were all lower than those before treatment (all P<0.01). Conclusion Ultrasound-guided intra-articular injection of etanercept was safe and effective for treatment of HA.
查看全文  查看/发表评论  下载PDF阅读器
关闭